DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0050398 A1 Bockmuehl Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0050398 A1 Bockmuehl Et Al US 2008.0050398A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0050398 A1 Bockmuehl et al. (43) Pub. Date: Feb. 28, 2008 (54) COMPOSITION COMPRISING (30) Foreign Application Priority Data BETA-DEFENSIN 2 Mar. 29, 2005 (DE).......................... 10 2005 O14 687.2 (76) Inventors: Dirk Bockmuehl, Wuppertal (DE); Publication Classification He-Marie Hoehne, Duesseldorf (51) Int. Cl. (DE) A6IR 39/02 (2006.01) AOIN 25/00 (2006.01) Correspondence Address: 52) U.S. Cl. ......................................... 424/1901: 424/405 WOODCOCKWASHIBURN LLP (52) s CIRA CENTRE, 12TH FLOOR (57) ABSTRACT 2929 ARCH STREET PHILADELPHIA, PA 19104-2891 (US) The invention relates to compositions comprising at least 9 one peptide with a structure or structural pattern of B-de (21) Appl. No.: 11/864,386 fensin 2 and/or its derivatives, especially human B-defensin 2. The compositions are selected in particular from cosmetic (22) Filed: Sep. 28, 2007 and/or pharmaceutical compositions, cleaning and/or wash ing agents, water-treatment agents and cooling lubricants. Related U.S. Application Data The invention also relates to the use of peptides with a structure or structural pattern of B-defensin 2 and/or its (63) Continuation of application No. PCT/EP2006/ derivatives, especially human f-defensin 2, as an antimi 002760, filed on Mar. 25, 2006. crobial active ingredient in the aforementioned agents. US 2008/0050398 A1 Feb. 28, 2008 COMPOSITION COMPRISING BETA-DEFENSIN 2 0011. There is a need for new antimicrobial agents or compositions containing them, which do not damage the CROSS-REFERENCE TO RELATED skin microflora as comprehensively, to be made available. APPLICATIONS 0012. There is a particular need for making available 0001) This application is a continuation of PCT/EP2006/ antimicrobial agents that are more effective against body 002760 filed Mar. 25, 2006, which claims the benefit of DE odor than the agents known so far and that are selectively 10 2005 014 687.2, filed Mar. 29, 2005, the complete active against the odor-forming microorganisms. disclosures of which are hereby incorporated by reference in their entirety. SUMMARY OF THE INVENTION 0013 The invention features compositions comprising at FIELD OF THE INVENTION least one B-defensin 2 polypeptide. In some aspects, the polypeptide has SEQ ID NO:1, or a derivative thereof, 0002 The object of the present invention is compositions wherein X of SEQ ID NO:1 is selected independently from comprising at least one peptide having a structure or a the group of the essential and non-essential amino acids. X structural pattern of B-defensin 2 and/or its derivatives, can be Cys, Gly, Thr, or Lys. X can be independently Thr or especially human B-defensin 2. In particular, the composi Gly at position 29, Cys at position 8, 15, 20, 30, 37, or 38, tions are selected from cosmetic and/or pharmaceutical or Lys at position 39 or 40. preparations, washing and/or cleaning agents, water-treat ment agents and cooling lubricants. A further object of the 0014. In some aspects, the compositions comprise at least invention is the use of at least one peptide with a structure one B-defensin 2 polypeptide having SEQ ID NO:2, or a or a structural pattern of B-defensin 2 and/or its derivatives, derivative thereof. In some aspects, the compositions com especially human B-defensin 2, as an antimicrobial agent in prise at least one f-defensin 2 polypeptide having SEQ ID the means listed. NO:3, or a derivative thereof. 0015. In the inventive compositions, the B-defensin 2 BACKGROUND OF THE INVENTION polypeptide or derivative thereof can be present at a con 0003. The disclosures of each patent, patent application, centration of 10 ng/ml to 100 ug/ml. The B-defensin 2 and publication cited or described in this document are polypeptide or derivative thereof can be present at a con hereby incorporated herein by reference, in their entireties. centration of 0.00001 to 50% by weight. 0016. The invention also features compositions compris 0004 Use of antimicrobial substances in compositions ing at least one B-defensin 3 polypeptide having SEQ ID Such as cosmetics, pharmaceutical products, washing and/or NO:4 or 5, or a derivative thereof. In some aspects, the cleaning agents, as well as water-treatment agents and B-defensin 3 polypeptide or derivative thereof is present at cooling lubricants, is known at the state of the art. a concentration of 0.00001 to 50% by weight. 0005 If these antimicrobial substances come into contact 0017. The inventive compositions can further comprise at with human skin in particular, that is usually linked with least one deodorizing agent or antiperspirant, at least one poor tolerance by the skin or undesired skin reactions. Such sebum regulator, at least one anti-inflammatory agent, and/ as irritations, reddenings, and sensitization reactions. or at least one prebiotic agent. 0006 Body odor, for instance, arises from the degrada 0018. Also featured are methods for reducing or prevent tion of constituents of perspiration by bacteria of the skin ing microbial contamination of washing agents, cleaning flora. It is also known that many antibacterial agents have agents, cosmetics, pharmaceuticals, filter media, construc poor action against body odor. tion materials, or water treatment agents. The methods 0007 Microbial activity is the cause, or a significant generally comprise admixing an effective amount of any one factor in, development of bad skin or pimples as well as or combination of the inventive compositions described and dandruff. exemplified herein with the washing agents, cleaning agents, cosmetics, pharmaceuticals, filter media, construction mate 0008 Use of antimicrobial agents in cosmetic and/or rials, or water treatment agents. In some aspects, the cos pharmaceutical preparations can, among other things, metics are deodorants, dental care agents, or oral care reduce dandruff, reduce body odor, improve the status of bad agents. In some aspects, the water treatment agents are used skin, and protect from, or treat, infections, particularly of to treat water in closed-loop circulation, or to treat water that sensitive and/or irritated skin. is used as a cooling lubricant. 0009 If the antimicrobial agents are used in cosmetic preparations, they usually act unselectively on the organisms 0019. Also featured are methods for reducing growth of microbes on the skin, which microbes are harmful to the in the skin flora and inhibit not only the harmful microor skin. The methods generally comprise administering to the ganisms on the skin, but also the useful ones (especially in skin an effective amount of the inventive compositions in the face, on the head skin, and under the armpits). combination with at least one prebiotically active agent. In 0010 This destruction of the skin flora often results in a Some aspects, the prebiotically active agent is a plant extract, possible short-term improvement of the corresponding sta glycerol monoalkyl ether, or ester of an organic acid. In tus of the skin followed, after terminating the treatment, by Some aspects, the microbes are coagulase-positive Staphy a reestablishment of the equilibrium of the various skin lococcus spp., Propionibacterium acnes, Candida albicans, microorganisms, which can sometimes be shifted toward Malassezia furfur, Corynebacterium spp. or Peptostrepto increased occurrence of pathogenic/harmful microorgan coccus spp. The Staphylococcus spp. can be Staphylococcus 1SS. Ca,S. US 2008/0050398 A1 Feb. 28, 2008 0020. The invention also features methods for reducing 0032. Furthermore, circulating water systems, for water the growth of microbes that are harmful to the mouth, treatment, or cooling lubricant systems, are often affected by comprising exposing the mouth or a dental prosthesis to an bacterial contaminants (frequently by bacteria of the genus effective amount of the inventive compositions in combina Pseudomonas and/or other aqueous microorganisms) which tion with at least one prebiotically active agent as described should be attacked by adding antimicrobial agents to the and exemplified herein. cooling lubricant or water-treatment agent in question. 0033. Therefore it is a further objective of the present DETAILED DESCRIPTION OF ILLUSTRATIVE invention to provide new antimicrobially active cooling EMBODIMENTS lubricants and/or water-treatment agents that comprise 0021. By use of molecular biology methods, the follow intentionally effective antimicrobial agents. ing characteristics were found according to the invention to 0034. These objectives are attained by compositions con be typical of persons with strong body odor: taining at least one peptide having a structure or structural 0022) a) reduced proportion of Staphylococcus epidermi pattern of B-defensin 2 according to SEQ ID NO: 1 and/or dis its derivatives, in which X is selected independently from the group of the essential and nonessential amino acids, 0023 b) increased proportion of Staphylococcus hominis especially human B-defensin 2. 0024 c) slightly increased proportion of Anaerococcus 0035. The defensins are antimicrobial peptides with short Octavius chain length (10 to 50 amino acids) which have been found in, among other places, epithelial tissue of both humans and 0.025 d) slightly increased proportion of Corynebacte animals. rium species. 0036). In humans, the B-defensins occur primarily in the 0026. Thus there is a need for substances that shift the mucous membranes and epithelial cells, especially in or on microflora profile of strong-smelling Subjects or of Subjects the skin. Human B-defensin 1 (hBD1) is found predomi with unpleasant body odor toward the microflora profile of nantly in the kidneys, saliva, lungs and skin, while human weakly-smelling Subjects, especially odor-neutral Staphylo B-defensin 2 (hbd2) is expressed primarily in the skin, the cocci, promote S. epidermidis in particular, and simulta trachea and the lungs if there is a bacterial stimulus. neously prevent growth of odor-forming Staphylocci, espe 0037 According to the invention "peptides having a cially of S.
Load more

Recommended publications
  • Isolation, Identification and Characterization of Allelochemicals/Natural Products
    Isolation, Identification and Characterization of Allelochemicals/Natural Products Isolation, Identification and Characterization of Allelochemicals/Natural Products Editors DIEGO A. SAMPIETRO Instituto de Estudios Vegetales “Dr. A. R. Sampietro” Universidad Nacional de Tucumán, Tucumán Argentina CESAR A. N. CATALAN Instituto de Química Orgánica Universidad Nacional de Tucumán, Tucumán Argentina MARTA A. VATTUONE Instituto de Estudios Vegetales “Dr. A. R. Sampietro” Universidad Nacional de Tucumán, Tucumán Argentina Series Editor S. S. NARWAL Haryana Agricultural University Hisar, India Science Publishers Enfield (NH) Jersey Plymouth Science Publishers www.scipub.net 234 May Street Post Office Box 699 Enfield, New Hampshire 03748 United States of America General enquiries : [email protected] Editorial enquiries : [email protected] Sales enquiries : [email protected] Published by Science Publishers, Enfield, NH, USA An imprint of Edenbridge Ltd., British Channel Islands Printed in India © 2009 reserved ISBN: 978-1-57808-577-4 Library of Congress Cataloging-in-Publication Data Isolation, identification and characterization of allelo- chemicals/natural products/editors, Diego A. Sampietro, Cesar A. N. Catalan, Marta A. Vattuone. p. cm. Includes bibliographical references and index. ISBN 978-1-57808-577-4 (hardcover) 1. Allelochemicals. 2. Natural products. I. Sampietro, Diego A. II. Catalan, Cesar A. N. III. Vattuone, Marta A. QK898.A43I86 2009 571.9’2--dc22 2008048397 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying or otherwise, without the prior permission of the publisher, in writing. The exception to this is when a reasonable part of the text is quoted for purpose of book review, abstracting etc.
    [Show full text]
  • IN SILICO ANALYSIS of FUNCTIONAL Snps of ALOX12 GENE and IDENTIFICATION of PHARMACOLOGICALLY SIGNIFICANT FLAVONOIDS AS
    Tulasidharan Suja Saranya et al. Int. Res. J. Pharm. 2014, 5 (6) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Research Article IN SILICO ANALYSIS OF FUNCTIONAL SNPs OF ALOX12 GENE AND IDENTIFICATION OF PHARMACOLOGICALLY SIGNIFICANT FLAVONOIDS AS LIPOXYGENASE INHIBITORS Tulasidharan Suja Saranya, K.S. Silvipriya, Manakadan Asha Asokan* Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Viswa Vidyapeetham University, AIMS Health Sciences Campus, Kochi, Kerala, India *Corresponding Author Email: [email protected] Article Received on: 20/04/14 Revised on: 08/05/14 Approved for publication: 22/06/14 DOI: 10.7897/2230-8407.0506103 ABSTRACT Cancer is a disease affecting any part of the body and in comparison with normal cells there is an elevated level of lipoxygenase enzyme in different cancer cells. Thus generation of lipoxygenase enzyme inhibitors have suggested being valuable. Individual variation was identified by the functional effects of Single Nucleotide Polymorphisms (SNPs). 696 SNPs were identified from the ALOX12 gene, out of which 73 were in the coding non-synonymous region, from which 8 were found to be damaging. In silico analysis was performed to determine naturally occurring flavonoids such as isoflavones having the basic 3- phenylchromen-4-one skeleton for the pharmacological activity, like Genistein, Diadzein, Irilone, Orobol and Pseudobaptigenin. O-methylated isoflavones such as Biochanin, Calycosin, Formononetin, Glycitein, Irigenin, 5-O-Methylgenistein, Pratensein, Prunetin, ψ-Tectorigenin, Retusin and Tectorigenine were also used for the study. Other natural products like Aesculetin, a coumarin derivative; flavones such as ajoene and baicalein were also used for the comparative study of these natural compounds along with acteoside and nordihydroguaiaretic acid (antioxidants) and active inhibitors like Diethylcarbamazine, Zileuton and Azelastine as standard for the computational analysis.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Chronic Venous Insufficiency/CVI
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Chronic Venous Insufficiency/CVI Chemical Activity Count (+)-AROMOLINE 1 (+)-CATECHIN 5 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 1 (+)-PRAERUPTORUM-A 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (-)-ACETOXYCOLLININ 1 (-)-APOGLAZIOVINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 1 (-)-BORNYL-FERULATE 1 (-)-BORNYL-P-COUMARATE 1 (-)-CANADINE 1 (-)-EPICATECHIN 4 (-)-EPICATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN 1 (-)-EPIGALLOCATECHIN-3-O-GALLATE 2 (-)-EPIGALLOCATECHIN-GALLATE 3 (-)-HYDROXYJASMONIC-ACID 1 (-)-N-(1'-DEOXY-1'-D-FRUCTOPYRANOSYL)-S-ALLYL-L-CYSTEINE-SULFOXIDE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 1 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 Chemical Activity Count 1,7-BIS(4-HYDROXY-3-METHOXYPHENYL)-1,6-HEPTADIEN-3,5-DIONE 1 1,8-CINEOLE 1 1-(METHYLSULFINYL)-PROPYL-METHYL-DISULFIDE 1 1-ETHYL-BETA-CARBOLINE 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 10-GINGEROL 1 12-(4'-METHOXYPHENYL)-DAURICINE 1 12-METHOXYDIHYDROCOSTULONIDE 1 13',II8-BIAPIGENIN 1 13-HYDROXYLUPANINE 1 14-ACETOXYCEDROL 1 14-O-ACETYL-ACOVENIDOSE-C 1 16-HYDROXY-4,4,10,13-TETRAMETHYL-17-(4-METHYL-PENTYL)-HEXADECAHYDRO- 1 CYCLOPENTA[A]PHENANTHREN-3-ONE 2,3,7-TRIHYDROXY-5-(3,4-DIHYDROXY-E-STYRYL)-6,7,8,9-TETRAHYDRO-5H-
    [Show full text]
  • Ep 3138585 A1
    (19) TZZ¥_¥_T (11) EP 3 138 585 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.03.2017 Bulletin 2017/10 A61L 27/20 (2006.01) A61L 27/54 (2006.01) A61L 27/52 (2006.01) (21) Application number: 16191450.2 (22) Date of filing: 13.01.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Gousse, Cecile GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 74230 Dingy Saint Clair (FR) PL PT RO RS SE SI SK SM TR • Lebreton, Pierre Designated Extension States: 74000 Annecy (FR) BA ME •Prost,Nicloas 69440 Mornant (FR) (30) Priority: 13.01.2010 US 687048 26.02.2010 US 714377 (74) Representative: Hoffmann Eitle 30.11.2010 US 956542 Patent- und Rechtsanwälte PartmbB Arabellastraße 30 (62) Document number(s) of the earlier application(s) in 81925 München (DE) accordance with Art. 76 EPC: 15178823.9 / 2 959 923 Remarks: 11709184.3 / 2 523 701 This application was filed on 29-09-2016 as a divisional application to the application mentioned (71) Applicant: Allergan Industrie, SAS under INID code 62. 74370 Pringy (FR) (54) STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES (57) The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. EP 3 138 585 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 138 585 A1 Description CROSS REFERENCE 5 [0001] This patent application is a continuation-in-part of U.S.
    [Show full text]
  • Isolation and Identification of Chemical Constituents from Zhideke Granules by Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry
    Hindawi Journal of Analytical Methods in Chemistry Volume 2020, Article ID 8889607, 16 pages https://doi.org/10.1155/2020/8889607 Research Article Isolation and Identification of Chemical Constituents from Zhideke Granules by Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry Guangqiang Huang ,1 Jie Liang ,1,2,3 Xiaosi Chen,1 Jing Lin,1 Jinyu Wei,1 Dongfang Huang,1 Yushan Zhou,1 Zhengyi Sun,4 and Lichun Zhao 1,3 1College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China 2Guangxi Key Laboratory of Zhuang and Yao Ethnic Medicine, Nanning 530200, China 3Guangxi Zhuang Yao Medicine Center of Engineering and Technology, Nanning 530200, China 4Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China Correspondence should be addressed to Jie Liang; [email protected] and Lichun Zhao; [email protected] Received 25 August 2020; Accepted 8 December 2020; Published 29 December 2020 Academic Editor: Luca Campone Copyright © 2020 Guangqiang Huang et al. ,is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Chemical constituents from Zhideke granules were rapidly isolated and identified by ultra-performance liquid chromatography (UPLC) coupled with hybrid quadrupole-orbitrap mass spectrometry (MS) in positive and negative ion modes using both full scan and two-stage threshold-triggered mass modes. ,e secondary fragment ion information of the target compound was selected and compared with the compound reported in databases and related literatures to further confirm the possible compounds. A total of 47 chemical constituents were identified from the ethyl acetate extract of Zhideke granules, including 21 flavonoids and glycosides, 9 organic acids, 4 volatile components, 3 nitrogen-containing compounds, and 10 other compounds according to the frag- mentation patterns, relevant literature, and MS data.
    [Show full text]
  • Natural Products As Chemopreventive Agents by Potential Inhibition of the Kinase Domain in Erbb Receptors
    Supplementary Materials: Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErBb Receptors Maria Olivero-Acosta, Wilson Maldonado-Rojas and Jesus Olivero-Verbel Table S1. Protein characterization of human HER Receptor structures downloaded from PDB database. Recept PDB resid Resolut Name Chain Ligand Method or Type Code ues ion Epidermal 1,2,3,4-tetrahydrogen X-ray HER 1 2ITW growth factor A 327 2.88 staurosporine diffraction receptor 2-{2-[4-({5-chloro-6-[3-(trifl Receptor uoromethyl)phenoxy]pyri tyrosine-prot X-ray HER 2 3PP0 A, B 338 din-3-yl}amino)-5h-pyrrolo 2.25 ein kinase diffraction [3,2-d]pyrimidin-5-yl]etho erbb-2 xy}ethanol Receptor tyrosine-prot Phosphoaminophosphonic X-ray HER 3 3LMG A, B 344 2.8 ein kinase acid-adenylate ester diffraction erbb-3 Receptor N-{3-chloro-4-[(3-fluoroben tyrosine-prot zyl)oxy]phenyl}-6-ethylthi X-ray HER 4 2R4B A, B 321 2.4 ein kinase eno[3,2-d]pyrimidin-4-ami diffraction erbb-4 ne Table S2. Results of Multiple Alignment of Sequence Identity (%ID) Performed by SYBYL X-2.0 for Four HER Receptors. Human Her PDB CODE 2ITW 2R4B 3LMG 3PP0 2ITW (HER1) 100.0 80.3 65.9 82.7 2R4B (HER4) 80.3 100 71.7 80.9 3LMG (HER3) 65.9 71.7 100 67.4 3PP0 (HER2) 82.7 80.9 67.4 100 Table S3. Multiple alignment of spatial coordinates for HER receptor pairs (by RMSD) using SYBYL X-2.0. Human Her PDB CODE 2ITW 2R4B 3LMG 3PP0 2ITW (HER1) 0 4.378 4.162 5.682 2R4B (HER4) 4.378 0 2.958 3.31 3LMG (HER3) 4.162 2.958 0 3.656 3PP0 (HER2) 5.682 3.31 3.656 0 Figure S1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0170186 A1 Geers Et Al
    US 2003O1701.86A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0170186 A1 Geers et al. (43) Pub. Date: Sep. 11, 2003 (54) NOVEL FLAVONE GLYCOSIDE (52) U.S. Cl. .................................... 424/59; 514/27; 536/8 DERIVATIVES FOR USE IN COSMETICS, PHARMACEUTICALS AND NUTRITION (57) ABSTRACT (76) Inventors: Bernadette Geers, Duesseldorf (DE); The invention relates to flavone and isoflavone glycoside Ralf Otto, Bad Friedrichshall (DE); derivatives of general formula (I): A-C(=O)0), X Albrecht Weiss, Langenfeld (DE); Dirk O-Z-O-C(=O)-A) (I), wherein X-O-Z represents a Petersohn, Koeln (DE); Klaus Rudolf flavone or isoflavone glycoside Structure, wherein X repre Schroeder, Mettmann (DE); Kordula Sents a flavone or isoflavone parent Substance of formula Schlotmann, Duesseldorf (DE) (IIa) or (IIb), said (iso)flavone parent Substance being mono or multisubstituted and/or mono- or multireduced (hydro Correspondence Address: genated), wherein Z (Sugar) represents a mono-, di- or COGNIS CORPORATION polysaccharide which is acetally bonded to the radical X and 2500 RENAISSANCE BLVD., SUITE 200 is ester-Substituted with A n-times, A-C(=O) represent GULPH MILLS, PA 19406 ing an acyl radical on the flavone or isoflavone parent Substance, wherein A and A, independently of each other, (21) Appl. No.: 10/258,049 represent a polyunsaturated Cs-Cs-alkenyl radical with at least 4 isolated and/or at least 2 conjugated double bonds or (22) PCT Filed: Apr. 11, 2001 an arylaliphatic radical with 1-4 methylene groups between (86) PCT No.: PCT/EPO1/04151 the ester group and the aromatic ring, wherein C(=O)A represents an acyl radical on the Sugar Z, wherein n is a Publication Classification whole number (1,2,3,...) but not 0, wherein m is a whole number including 0 (0,1,2,3,...) and wherein R1,R2 and (51) Int.
    [Show full text]
  • Irigenin Exhibits Anticancer Activity Against Human Colon Cancer Cells
    Zhan et al Tropical Journal of Pharmaceutical Research July 2021; 20 (7): 1357-1363 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v20i7.6 Original Research Article Irigenin exhibits anticancer activity against human colon cancer cells via autophagy, inhibition of cell migration and invasion, and targeting of ERK/MAPK signal pathway Yan Zhan, Shuangxi Kong, Liang Fan, Jun Jiang* Department of Oncology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China *For correspondence: Email: [email protected]; Tel/Fax: 0086-02765696508 Sent for review: 20 October 2020 Revised accepted: 20 June 2021 Abstract Purpose: To study the anticancer effect of naturally-occurring irigenin isoflavonoid on colon cancer, and to determine the mechanism involved. Methods: The effect of irigenin on viability of normal and cancerous colon cells was assessed by MTT assay, while clonogenic assay was used to measure colony generation. Autophagy was examined by transmission electron microscopy (TEM) and western blotting. Transwell chamber assay was used to determine the influence of irigenin isoflavonoid on cell migration and invasion. The expression levels of ERK/MAPK signal pathway-associated proteins were assayed using Western blotting. Results: Irigenin significantly decreased the viability of Caco-2 colon cancer cells, in contrast to normal CCD841 colon cells, and produced concentration-dependent anti-proliferative effects (p < 0.05). The number of cell colonies in control group decreased significantly (p < 0.05) upon exposure to irigenin.
    [Show full text]
  • ( 12 ) United States Patent
    US010722444B2 (12 ) United States Patent ( 10 ) Patent No.: US 10,722,444 B2 Gousse et al. (45 ) Date of Patent : Jul. 28 , 2020 (54 ) STABLE HYDROGEL COMPOSITIONS 4,605,691 A 8/1986 Balazs et al . 4,636,524 A 1/1987 Balazs et al . INCLUDING ADDITIVES 4,642,117 A 2/1987 Nguyen et al. 4,657,553 A 4/1987 Taylor (71 ) Applicant: Allergan Industrie , SAS , Pringy (FR ) 4,713,448 A 12/1987 Balazs et al . 4,716,154 A 12/1987 Malson et al. ( 72 ) 4,772,419 A 9/1988 Malson et al. Inventors: Cécile Gousse , Dingy St. Clair ( FR ) ; 4,803,075 A 2/1989 Wallace et al . Sébastien Pierre, Annecy ( FR ) ; Pierre 4,886,787 A 12/1989 De Belder et al . F. Lebreton , Annecy ( FR ) 4,896,787 A 1/1990 Delamour et al. 5,009,013 A 4/1991 Wiklund ( 73 ) Assignee : Allergan Industrie , SAS , Pringy (FR ) 5,087,446 A 2/1992 Suzuki et al. 5,091,171 A 2/1992 Yu et al. 5,143,724 A 9/1992 Leshchiner ( * ) Notice : Subject to any disclaimer , the term of this 5,246,698 A 9/1993 Leshchiner et al . patent is extended or adjusted under 35 5,314,874 A 5/1994 Miyata et al . U.S.C. 154 (b ) by 0 days. 5,328,955 A 7/1994 Rhee et al . 5,356,883 A 10/1994 Kuo et al . (21 ) Appl . No.: 15 /514,329 5,399,351 A 3/1995 Leshchiner et al . 5,428,024 A 6/1995 Chu et al .
    [Show full text]
  • Pharmacology and Phytochemistry of Isoflavonoids from Iris Species
    Journal of Pharmacology & Clinical Research ISSN: 2473-5574 Review Article J of Pharmacol & Clin Res - Volume 3 Issue 2 July 2017 Copyright © All rights are reserved by Afroze Alam DOI: 10.19080/JPCR.2017.03.555609 Pharmacology and Phytochemistry of Isoflavonoids from Iris Species Disha Choudhary and Afroze Alam*1,2,3 1Institute of Pharmacy, Shri Jagdish Prasad Jhabarmal Tibrewala University, India 2Narayan Institute of Pharmacy, India 3School of Pharmacy, Shoolini University, India Submission: June 16, 2016; Published: July 13, 2017 *Corresponding author: Afroze Alam, Narayan Institute of Pharmacy, Jamuhar, Sasaram (Rohtas)-821305(Bihar)-India, Tel: ; Fax: ; Email: ; Abstract Iris is the largest and most complicated genus of family Iridaceae. Irises are mainly used as the ornamental plants, due to their colorful iris species species of iris have resulted in the isolation of flowers, or in the perfume industry, due to their violet like fragrance, but lot of were also used in many part of the worldsiris as medicinal plants for healing of a wide spectrum of diseases. The phytochemical investigations of various variety of secondary metabolites. Approximately more than two hundred compounds have been reported from the genus which includes flavonoids, isoflavonoids and their glycosides, benzoquinones triterpenoids and stilbenes glycosides. This genus is rich in isoflavonoidsIris which have a wide range of biological activity including anti-inflammatory, antioxidant and cancer chemo preventive properties. Nowadays phytochemical and pharmacological investigations bring new knowledge about chemical compounds in roots, leaves and flowers of the species, about their chemical content and possible pharmacological and medicinal usage. This review brings suchtogether as cancer, results cardiovascular of the iris research disorder, in last and few osteoporosisor decades, putting against together the bacterial the information and viral about infections.
    [Show full text]
  • Current Organic Chemistry, 2017, 21, 218-235 REVIEW ARTICLE
    Send Orders for Reprints to [email protected] 218 Current Organic Chemistry, 2017, 21, 218-235 REVIEW ARTICLE ISSN: 1385-2728 eISSN: 1875-5348 Impact Factor: Isoflavones, their Glycosides and Glycoconjugates. Synthesis and Biological Activity 1.949 BENTHAM SCIENCE Wiesaw Szeja1*, Grzegorz Grynkiewicz2 and Aleksandra Rusin3 1Silesian Technical University, Department of Chemistry, Krzywoustego 4, 44-100 Gliwice, Poland; 2Pharmaceutical Research Insti- tute, Rydygiera 8, 01-793 Warszawa, Poland; 3Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeze AK 15, 44-100 Gliwice, Poland Abstract: Glycosylation of small biologically active molecules, either of natural or synthetic origin, has a pro- found impact on their solubility, stability, and bioactivity, making glycoconjugates attractive compounds as therapeutic agents or nutraceuticals. A large proportion of secondary metabolites, including flavonoids, occur in plants as glycosides, which adds to the molecular diversity that is much valued in medicinal chemistry studies. The subsequent growing market demand for glycosidic natural products has fueled the development of various chemical and biotechnological methods of glycosides preparation. The review gives an extensive overview of the A R T I C L E H I S T O R Y processes of the synthesis of isoflavones and discusses recently developed major routes towards isoflavone-sugar Received: May 05, 2016 formation processes. Special attention is given to the derivatives of genistein, the main isoflavone recognized as a Revised: July 20, 2016 useful lead in several therapeutic categories, with particular focus on anticancer drug design. The utility of Accepted: September 22, 2016 chemical glycosylations as well as glycoconjugates preparation is discussed in some theoretical as well as practi- DOI: cal aspects.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tuberculosis
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tuberculosis Chemical Activity Count (+)-3-HYDROXY-9-METHOXYPTEROCARPAN 1 (+)-8HYDROXYCALAMENENE 1 (+)-ALLOMATRINE 1 (+)-ALPHA-VINIFERIN 3 (+)-AROMOLINE 1 (+)-CASSYTHICINE 1 (+)-CATECHIN 10 (+)-CATECHIN-7-O-GALLATE 1 (+)-CATECHOL 1 (+)-CEPHARANTHINE 1 (+)-CYANIDANOL-3 1 (+)-EPIPINORESINOL 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALBACIN 2 (+)-GALLOCATECHIN 3 (+)-HERNANDEZINE 1 (+)-ISOCORYDINE 2 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 2 (+)-T-CADINOL 1 (+)-VESTITONE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-3-HYDROXY-9-METHOXYPTEROCARPAN 1 (-)-ACANTHOCARPAN 1 (-)-ALPHA-BISABOLOL 2 (-)-ALPHA-HYDRASTINE 1 Chemical Activity Count (-)-APIOCARPIN 1 (-)-ARGEMONINE 1 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANESCACARPIN 1 (-)-CENTROLOBINE 1 (-)-CLANDESTACARPIN 1 (-)-CRISTACARPIN 1 (-)-DEMETHYLMEDICARPIN 1 (-)-DICENTRINE 1 (-)-DOLICHIN-A 1 (-)-DOLICHIN-B 1 (-)-EPIAFZELECHIN 2 (-)-EPICATECHIN 6 (-)-EPICATECHIN-3-O-GALLATE 2 (-)-EPICATECHIN-GALLATE 1 (-)-EPIGALLOCATECHIN 4 (-)-EPIGALLOCATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN-GALLATE 9 (-)-EUDESMIN 1 (-)-GLYCEOCARPIN 1 (-)-GLYCEOFURAN 1 (-)-GLYCEOLLIN-I 1 (-)-GLYCEOLLIN-II 1 2 Chemical Activity Count (-)-GLYCEOLLIN-III 1 (-)-GLYCEOLLIN-IV 1 (-)-GLYCINOL 1 (-)-HYDROXYJASMONIC-ACID 1 (-)-ISOSATIVAN 1 (-)-JASMONIC-ACID 1 (-)-KAUR-16-EN-19-OIC-ACID 1 (-)-MEDICARPIN 1 (-)-VESTITOL 1 (-)-VESTITONE 1
    [Show full text]